Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
3
27%
Ph phase_3
3
27%
Ph phase_1
3
27%
Ph phase_2
2
18%

Phase Distribution

3

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
3(27.3%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 22 (18.2%)
Phase 33 (27.3%)
N/A3 (27.3%)

Trials by Status

unknown19%
terminated19%
withdrawn19%
completed873%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT00021762Phase 2

Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV

Withdrawn
NCT00006495Phase 1

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

Completed
NCT00005758Phase 3

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

Completed
NCT00000943Not Applicable

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Completed
NCT00006153Phase 1

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

Terminated
NCT00001445Phase 1

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

Completed
NCT00002172Not Applicable

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

Completed
NCT00002359Phase 3

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

Completed
NCT00002173Not Applicable

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

Completed
NCT00005001Phase 2

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Completed
NCT00005002Phase 3

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Unknown

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11